Hasan Tahir

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi et al. · The Lancet · 2021 · 564 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +6

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

Philip J. Mease, Désirée van der Heijde, Robert Landewé et al. · Annals of the Rheumatic Diseases · 2018 · 301 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

Philip J. Mease, Josef S Smolen, Frank Behrens et al. · Annals of the Rheumatic Diseases · 2019 · 288 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Karel Pavelka, Alan Kivitz, Eva Dokoupilová et al. · Arthritis Research & Therapy · 2017 · 233 citations · Full text

Medicine, Immunology, Pharmacotherapy +17